Ibrutinib plus rituximab for the treatment of adult patients with Waldenström’s macroglobulinemia: a safety evaluation

References

• Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenstrom’s macroglobulinemia. Ann Oncol. 2005 Jan;16(1):132–138.
   PubMed Web of Science ®Google Scholar
• Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003 Apr;30(2):110–115.
   PubMed Web of Science ®Google Scholar
• McMaster ML. Familial Waldenstrom’s macroglobulinemia. Semin Oncol. 2003 Apr;30(2):146–152.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom’s macroglobulinemia. Ann Oncol. 2006 Mar;17(3):488–494.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Waldenstrom macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019 Feb;94(2):266–276.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Galani E, Matsouka C. Waldenström’s macroglobulinemia. Hematol Oncol Clin North Am. 1999 Dec;13(6):1351–1366.
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Musto P, Caers J, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018 Sep;32(9):1883–1898.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenstrom Macroglobulinaemia. Lancet Haematol. 2020 Nov;7(11):e827–e837.
   PubMed Web of Science ®Google Scholar
• Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom’s Macroglobulinemia. Blood. 2016 Sep 8;128(10):1321–1328.
   PubMed Web of Science ®Google Scholar
• Buske C, Seymour JF. Immunochemotherapy in Waldenstrom macroglobulinemia - still the backbone of treatment. Leuk Lymphoma. 2015;56(9):2489–2490.
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, et al. How I treat rituximab refractory patients with WM. Oncotarget. 2018 Dec 7;9(96):36824–36825.
   PubMedGoogle Scholar
• Castillo JJ, Kanan S, Meid K, et al. Rituximab intolerance in patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2016 Aug;174(4):645–648.
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012 Aug 30;367(9):826–833.
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Hunter Z. MYD88 Mutations and Response to Ibrutinib in Waldenstrom’s Macroglobulinemia. N Engl J Med. 2015 Aug 6;373(6):584–586.
   PubMed Web of Science ®Google Scholar
• Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014 May 1;123(18):2791–2796.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010 Apr;47(2):115–123.
   PubMed Web of Science ®Google Scholar
• Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004 Jun 21;199(12):1659–1669.
   PubMed Web of Science ®Google Scholar
• Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;2(6):676–690.
   PubMed Web of Science ®Google Scholar
• Salar A, Avivi I, Bittner B, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014 Jun 10;32(17):1782–1791.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004 Oct;45(10):2047–2055.
   PubMed Web of Science ®Google Scholar
• Regazzi MB, Iacona I, Avanzini MA, et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit. 2005 Dec;27(6):785–792.
   PubMed Web of Science ®Google Scholar
• Davies A, Merli F, Mihaljevic B, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014 Mar;15(3):343–352.
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, et al. The current role of BTK inhibitors in the treatment of Waldenstrom’s Macroglobulinemia. Expert Rev Anticancer Ther. 2020 Aug;20(8):663–674.
   PubMed Web of Science ®Google Scholar
• Marostica E, Sukbuntherng J, Loury D, et al. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol. 2015 Jan;75(1):111–121.
   PubMed Web of Science ®Google Scholar
• de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect. 2015 Aug;3(4):e00156.
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer. 2012 Jan 15;118(2):434–443.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28;124(9):1404–1411.
   PubMed Web of Science ®Google Scholar
• Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301–307.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström’s Macroglobulinemia With Rituximab. J Clin Oncol. 2002 May 1;20(9):2327–2333.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Laribi K, Poulain S, Willems L, et al. Bendamustine plus rituximab in newly-diagnosed Waldenstrom macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. Epub 2018 Dec 12. 2019 Jul;186(1):146-149.
   Web of Science ®Google Scholar
• Tedeschi A, Picardi P, Ferrero S, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2015 Mar 14:56(9):2637-42.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):133–135.
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009 Jan;23(1):153–161.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007 Aug 1;25(22):3344–3349.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Gavriatopoulou M, Kyrtsonis MC, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study. Blood. 2015 Sep 10;126(11):1392–1394.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013 Nov 7;122(19):3276–3282.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia. Am J Hematol. 2010 Sep;85(9):670–674.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10;28(8):1422–1428.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Meid K, Gustine JN, et al. Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in Waldenstrom Macroglobulinemia. Clin Cancer Res. 2018 Jul 15;24(14):3247–3252.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom’s macroglobulinemia. Blood. 2014 Jul 24;124(4):503–510.
   PubMed Web of Science ®Google Scholar
• Meid K, Dubeau T, Sevems P. al. e. Long term follow-up of a prospective clinical trial of carfilzomib, rituximab and dexamethasone (CaRD) in Waldenstrom’s macroglobulinemia. Blood. 2017;124:503–510.
   Google Scholar
• Castillo JJ, Gustine JN, Meid K, et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstrom macroglobulinaemia. Br J Haematol. 2018 Apr;181(1):77–85.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015 Apr 9;372(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Buske C, Tedeschi A, Trotman J, et al. Ibrutinib treatment in Waldenström’s Macroglobulinemia: follow-up efficacy and safety from the iNNOVATETM study. Blood. 2018;S0190-9622(19):33308-0.
   PubMed Web of Science ®Google Scholar
• Trotman J, Buske C, Tedeschi A, et al. Long-term follow-up of ibrutinib treatment for rituximab-refractory Waldenström’s Macroglobulinemia: final analysis of the open-label substudy of the Phase 3 iNNOVATETM trial. Blood. 2020;136(Supplement 1):38–39.
   Web of Science ®Google Scholar
• Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom Macroglobulinemia. J Clin Oncol. 2018 Sep 20;36(27):2755–2761.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Itchaki G, Paludo J, et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 Jan 24;133(4):299–305.
   PubMed Web of Science ®Google Scholar
• Xu L, Tsakmaklis N, Yang G, et al. Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia. Blood. 2017 May 4;129(18):2519–2525.
   PubMed Web of Science ®Google Scholar
• Buske C, Tedeschi A, Trotman J, et al. Five-year follow-up of ibrutinib plus rituximab vs placebo plus rituximab for Waldenstrom’s Macroglobulinemia: final analysis from the randomized Phase 3 iNNOVATETM study. Blood. 2020;136(Supplement 1):24–26.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004 Dec 1;101(11):2593–2598.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia. Ann Oncol. 2004 Oct;15(10):1481–1483.
   PubMed Web of Science ®Google Scholar
• Tesfa D, Palmblad J. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol. 2011 Dec;4(6):619–625.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb;18(2):241–250.
   PubMed Web of Science ®Google Scholar
• Abeykoon JP, Zanwar S, Ansell SM, et al. Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom macroglobulinaemia: practice patterns, toxicities and outcomes. Br J Haematol. 2020 Feb;188(3):394–403.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Salman Z, Buske C. Ibrutinib and Rituximab in Waldenstrom’s Macroglobulinemia. N Engl J Med. 2018 Nov 15;379(20):1975–1976.
   PubMed Web of Science ®Google Scholar
• Baron M, Zini JM, Challan Belval T, et al. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Leuk Lymphoma. 2017 Dec;58(12):2981–2982.
   PubMed Web of Science ®Google Scholar
• Brown JR, Moslehi J, O’Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 Oct;102(10):1796–1805.
   PubMed Web of Science ®Google Scholar
• Ganatra S, Sharma A, Shah S, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018 Dec;4(12):1491–1500.
   PubMedGoogle Scholar
• Caldeira D, Alves D, Costa J, et al. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One. 2019;14(2):e0211228.
   PubMed Web of Science ®Google Scholar
• Wiczer TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017 Sep 12;1(20):1739–1748.
   PubMed Web of Science ®Google Scholar
• Gustine JN, Meid K, Dubeau TE, et al. Atrial fibrillation associated with ibrutinib in Waldenstrom macroglobulinemia. Am J Hematol. 2016 Jun;91(6):E312–313.
   PubMed Web of Science ®Google Scholar
• Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129:2581–2584.
   PubMed Web of Science ®Google Scholar
• Bye AP, Unsworth AJ, Vaiyapuri S, et al. Ibrutinib inhibits platelet integrin alphaIIbbeta3 outside-in signaling and thrombus stability but not adhesion to collagen. Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2326–2335.
   PubMed Web of Science ®Google Scholar
• Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014 Dec 18;124(26):3991–3995.
   PubMed Web of Science ®Google Scholar
• Brown JR, Moslehi J, Ewer MS, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br J Haematol. 2019 Feb;184(4):558–569.
   PubMed Web of Science ®Google Scholar
• Mock J, Kunk PR, Palkimas S, et al. Risk of major bleeding with ibrutinib. Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):755–761.
   PubMed Web of Science ®Google Scholar
• Yun S, Vincelette ND, Acharya U, et al. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk. 2017 Jan;17(1):31–37 e13.
   PubMed Web of Science ®Google Scholar
• Ambinder AJ, Hambley B, Shanbhag S, et al. Ibrutinib-associated hemophagocytic lymphohistiocytosis: a case series from Johns Hopkins. Am J Hematol. 2019 Nov;94(11):E296–E299.
   PubMed Web of Science ®Google Scholar
• Shaikh H, Khattab A, Faisal MS, et al. Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature. J Oncol Pharm Pract. 2019 Jul;25(5):1265–1270.
   PubMed Web of Science ®Google Scholar
• Jensen AB, Stausbol-Gron B, Riber-Hansen R, et al. Ibrutinib-associated skin toxicity: a case of maculopapular rash in a 79-Year old caucasian male patient with relapsed Waldenstrom’s Macroglobulinemia and review of the literature. Dermatol Reports. 2017 Mar 13;9(1):6976.
   PubMed Web of Science ®Google Scholar
• Singer S, Tan SY, Dewan AK, et al. Cutaneous eruptions from ibrutinib resembling EGFR inhibitor-induced dermatologic adverse events. J Am Acad Dermatol. 2019 Dec 20;S0190-9622(19):33308-0.
   Google Scholar
• Castillo JJ, Gustine JN, Meid K, et al. Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia. Haematologica. 2018 Jul;103(7):e307–e310.
   PubMed Web of Science ®Google Scholar
• Niemann CU, Herman SE, Maric I, et al. Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib--findings from an investigator-initiated Phase II study. Clin Cancer Res. 2016 Apr 1;22(7):1572–1582.
   PubMed Web of Science ®Google Scholar
• Ping L, Ding N, Shi Y, et al. The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Oncotarget. 2017 Jun 13;8(24):39218–39229.
   PubMedGoogle Scholar
• Ren L, Campbell A, Fang H, et al. Analysis of the effects of the Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib on monocyte fcgamma receptor (FcgammaR) function. J Biol Chem. 2016 Feb 5;291(6):3043–3052.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstrom’s Macroglobulinemia. N Engl J Med. 2018 Jun 21;378(25):2399–2410.
   PubMed Web of Science ®Google Scholar
• Agency EM. Imbruvica, INN-ibrutinib. Summary of product characteristics. [ cited 2020 Apr 23]. Available from: https://ec.europa.eu/health/documents/community-register/2014/20141021129815/anx_129815_el.pdf
   Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009 Aug 10;27(23):3830–3835.
   PubMed Web of Science ®Google Scholar
• Buske C, Dimopoulos M, Grunenberg A, et al. Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) as first - line treatment of Waldenstrom’s Macroglobulinemia: results of a prospectively randomized multicenter European Phase II trial. Blood. 2020;136:26.
   Web of Science ®Google Scholar
• Souchet L, Levy V, Ouzegdouh M, et al. Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom’s macroglobulinemia. Am J Hematol. 2016 Aug;91(8):782–786.
   PubMed Web of Science ®Google Scholar
• Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009 Jan 10;27(2):250–255.
   PubMed Web of Science ®Google Scholar
• Leleu X, Tamburini J, Roccaro A, et al. Balancing risk versus benefit in the treatment of Waldenstrom’s Macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma. 2009 Mar;9(1):71–73.
   PubMedGoogle Scholar
• Laribi K, Poulain S, Willems L, et al. Bendamustine plus rituximab in newly-diagnosed Waldenstrom macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2019 Jul;186(1):146–149.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Brugger W, Damaj G, et al. Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel - an update. Leuk Lymphoma. 2016;57(4):766–782.
   PubMed Web of Science ®Google Scholar
• Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014 Mar 13;123(11):1637–1646.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Xu L, Gustine JN, et al. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019 Nov;187(3):356-363.
   Web of Science ®Google Scholar
• A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study' Blood. 2020 Oct 29;136(18):2038-2050.
   Google Scholar
• Tam CS, LeBlond V, Novotny W, et al. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia. Future Oncol. 2018 Sep;14(22):2229–2237.
   PubMed Web of Science ®Google Scholar
• Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020 Feb;7(2):e112–e121.
   PubMed Web of Science ®Google Scholar
• Yang G, Wang J, Munshi M, et al. A novel HCK and BTK dual inhibitor Kin-8194 shows superior activity over ibrutinib and overcomes BTKC481S mediated ibrutinib resistance in vitro and in vivo in MYD88 mutated B-Cell lymphomas. Blood. 2019;134:394.
   Web of Science ®Google Scholar
• Kuiatse I, Baladandayuthapani V, Lin HY, et al. Targeting the spleen tyrosine kinase with fostamatinib as a strategy against Waldenstrom Macroglobulinemia. Clin Cancer Res. 2015 Jun 1;21(11):2538–2545.
   PubMed Web of Science ®Google Scholar
• Munshi M, Liu X, Chen JG, et al. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 2020 Jan 31;10(1):12.
   PubMed Web of Science ®Google Scholar